Skip to main content
. 2020 Dec 7;4(23):6023–6033. doi: 10.1182/bloodadvances.2020002711

Figure 2.

Figure 2.

TTP according to levels of protein expression. (A) TTP in patients with low and high levels of proteins connected to lenalidomide activity, including cereblon, Aiolos, Ikaros, IRF4, and AGO2. (B) TTP in patients with high and low levels of proteins connected to bortezomib activity, including gankyrin, PSMD1, and PSMD4. CSH models were fitted for each protein. The TTP of MM patients is represented depending on protein status. Cutoff Finder (http://molpath.charite.de/cutoff) was used to obtain the optimal cutoff, which was defined as that producing the most significant split discriminating between good and poor survival by examining all the possible cutoffs using the log-rank test. (C) TTP according to the GCR/XPO1 ratio. The log-rank test was performed for GCR/XPO1 ratio. A CSH model was fitted for GCR/XPO1 ratio using dichotomized values based on the optimal cutoff estimated with Cutoff Finder, which was defined as that producing the most significant split discriminating between good and poor survival by examining all the possible cutoffs using the log-rank test.